Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + lenvatinib + sintilimab vs TACE + lenvatinib in HCC with portal vein tumor thrombus
ChiCTR2200066830Phase 3Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatocellular carcinoma (HCC) comparing TACE + lenvatinib + sintilimab with TACE + lenvatinib (2 arms). Primary endpoint: Time to Progression. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
lenvatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200066830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066830.